Featured Research Search Results

Research Study on the Genetics of Breast Cancer

Clinicaltrials.gov identifier:
NCT06773897

Surveys, Registries, Interviews
A registry for anyone aged 18 and older who lives in the United States

Evaluating the Safety of Nipple Sparing Mastectomy in Women With a High Risk for Breast Cancer

Clinicaltrials.gov identifier:
NCT06888388

Prevention
Study for people considering double mastectomy to reduce breast cancer risk

Experiences with Genetic Counseling Among Individuals with a BRCA1 or BRCA2 Genetic Mutation

Surveys, Registries, Interviews
Survey for people with a positive BRCA1 and/or BRCA2 mutation.

NePtune: Using PARP Inhibitors Before Surgery in Localized Prostate Cancer

Clinicaltrials.gov identifier:
NCT05498272

Treatment
Treatment study for people with intermediate- or high-risk prostate cancer with certain tumor mutations

Vaccine for People at High Risk for Pancreatic Cancer

Clinicaltrials.gov identifier:
NCT05013216

Prevention
Phase 1 pancreatic cancer prevention study for people at high risk

Exploring How BRCA+ Previvors Experience Joy

Surveys, Registries, Interviews
Survey and interviews about joy and emotions following genetic results for BRCA+ previvors

A Study of Fallopian Tube Removal with Delayed Ovary Removal to Lower Ovarian Cancer Risk (TUBA-WISP-II)

Clinicaltrials.gov identifier:
NCT04294927

Prevention
Prevention study for women at high risk for ovarian cancer

Using a Shorter Type of MRI as a Screening Tool for People at High Risk for Prostate Cancer

Clinicaltrials.gov identifier:
NCT05384535

Prevention
Screening for people at high risk for prostate cancer

Study of a New Investigational Inhibitor to Treat People with Advanced Solid Tumors

Clinicaltrials.gov identifier:
NCT05932862

Treatment
Treatment study for people with advanced solid tumors

Using a PARP Inhibitor and Oral Chemotherapy to Treat Advanced Solid Tumors with a Mutation in BRCA1, BRCA2, PALB2, ATM or CHEK2

Clinicaltrials.gov identifier:
NCT06177171

Treatment
Phase 1 treatment study for metastatic solid tumors

Maintenance Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer with a BRCA Mutation or a Biomarker Called HRD

Clinicaltrials.gov identifier:
NCT06580314

Treatment
Phase 3 ovarian cancer treatment study for people with BRCA mutation or HRD

A Study of the PARP Inhibitor Saruparib Added to Standard Treatment for High Risk BRCA-Positive Prostate Cancer

Clinicaltrials.gov identifier:
NCT06952803

Treatment
Phase 3 treatment study for BRCA-positive high-risk prostate cancer

A New Targeted Therapy CX‑5461 to Treat Advanced Breast, Ovarian, Pancreatic or Prostate Cancer with Inherited or Tumor Mutations

Clinicaltrials.gov identifier:
NCT04890613

Treatment
Phase 1 treatment study for advanced or metastatic breast, ovarian, pancreatic or prostate cancer

Screening Study for Pancreatic Cancer in People with Inherited Mutations

Clinicaltrials.gov identifier:
NCT05058846

Prevention
Pancreatic cancer screening study for people with ATM, BRCA1, BRCA2 or PALB2 mutations

Studying a New PARP Inhibitor and Hormonal Therapy to Treat HER2-negative, HR-positive Metastatic Breast Cancer with a BRCA1, BRCA2, or PALB2 Mutation (EvoPAR BR01)

Clinicaltrials.gov identifier:
NCT06380751

Treatment
Phase 3 treatment study for HER2-negative, HR-positive metastatic breast cancer with a BRCA1, BRCA2 or PALB2 mutation

A Study to Compare Two Surgical Procedures in Women with BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer (SOROCk)

Clinicaltrials.gov identifier:
NCT04251052

Prevention
Ovarian cancer prevention for women with a BRCA1 mutation who still have their ovaries

Treating HER2-negative, Metastatic Breast Cancer with a BRCA or PALB2 Mutation Using a New Drug Combined with Olaparib

Clinicaltrials.gov identifier:
NCT06488378

Treatment
Treatment study for HER2-negative, metastatic breast cancer with a BRCA1/2 or PALB2 mutation

Pancreatic Cancer Screening Study (CAPS5)

Clinicaltrials.gov identifier:
NCT02000089

Prevention
Screening study for people at high risk for pancreatic cancer